In accordance with these findings, the expression of proliferation markers on CD4+ T cells 2 weeks after therapy initiation of ipilimumab and GM-CSF was increased in patients with metastatic prostate cancer [17]. This evidence concerns the gene CSF2 and metastatic prostate carcinoma.